Skip to content

Efficacy and Safety of an Early Aggressive Lipid-Lowering Strategy Using Triple Therapy After Mechanical Thrombectomy.

Aug 2026 · CNS Drugs · 0 citations · 36 references
Medicine

TL;DR

Triple therapy achieved faster and greater LDL-C reduction and improved clinical outcomes following EVT, particularly among patients with AIS due to ELVO from LAA, particularly among patients with AIS due to ELVO from LAA.

View source

Similar papers

Open access Aug 2026

Early discontinuation of dual antiplatelet therapy after PCI in patients at high bleeding risk: an OCT-guided clinical case

The application of OCT for the evaluation of stent strut endothelialization provides a robust rationale for shortening DAPT duration to 1 month in patients with high hemorrhagic risk, even in the presence of concomitant diabetes mellitus and multiple comorbidities.

A. Prokhorikhin, Yu. V. Kukushkina, D. D. Zubarev et al. · 0 citations
Open access Oct 2026

Prolonged low-dose intravenous thrombolysis in early recurrent stroke.

INTRODUCTION Treatment of acute ischemic stroke follows well-established guidelines and standards of care. However, the optimal management of ultra-early stroke recurrence remains unclear. We present outcomes of prolonged low-dose intravenous thrombolysis used as rescue therapy in this setting. MATERIAL AND METHODS T...

D. Černík, Jiří Neumann, Jan Macko et al. · 0 citations
Open access Sep 2026

Impact of stepwise dual antiplatelet therapy de-escalation in patients with multivessel disease undergoing drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial

Among patients with ACS undergoing DCB-only angioplasty, those with multivessel disease were associated with a higher risk of NACE than those with single-vessel disease and stepwise DAPT de-escalation and standard DAPT exhibited similar risk-benefit profiles in both subgroups.

C. Gao, Y. Zhang, X. He et al. · 0 citations
Open access Sep 2026

Add-On PCSK9 Inhibitor Therapy for Acute Stroke Attributable to Intracranial Atherosclerosis: A Randomized Clinical Trial.

BACKGROUND Intracranial atherosclerotic stenosis is a major cause of ischemic stroke with high recurrence rates despite intensive therapy. The efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) as adjunctive treatment in intracranial atherosclerotic stenosis remains unclear. METHODS We cond...

Yi-Ting Pan, Yuan-Hsiung Tsai, Hsu-Huei Weng et al. · 0 citations
Open access Aug 2026

Early evolocumab improves lipid profile, inflammation and short-term outcomes in non-revascularized CHIP-NSTEACS patients: a retrospective cohort study

Objective To evaluate the lipid-lowering efficacy, anti-inflammatory activity, and short-term prognostic benefit of early evolocumab plus statin in complex high-risk indicated non-revascularized non-ST-elevation acute coronary syndrome (CHIP-NSTEACS) patients. Methods This single-center retrospective cohort study conse...

Wen-Bin Jiang, Mei Liu, Xiaoshuan Xiong et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.